96 related articles for article (PubMed ID: 23746084)
1. Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant.
Radi M; Tintori C; Musumeci F; Brullo C; Zamperini C; Dreassi E; Fallacara AL; Vignaroli G; Crespan E; Zanoli S; Laurenzana I; Filippi I; Maga G; Schenone S; Angelucci A; Botta M
J Med Chem; 2013 Jul; 56(13):5382-94. PubMed ID: 23746084
[TBL] [Abstract][Full Text] [Related]
2. Exploring the chemical space around the privileged pyrazolo[3,4-d]pyrimidine scaffold: toward novel allosteric inhibitors of T315I-mutated Abl.
Vignaroli G; Mencarelli M; Sementa D; Crespan E; Kissova M; Maga G; Schenone S; Radi M; Botta M
ACS Comb Sci; 2014 Apr; 16(4):168-75. PubMed ID: 24597676
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J
Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
[TBL] [Abstract][Full Text] [Related]
5. Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant.
Hong S; Kim J; Yun SM; Lee H; Park Y; Hong SS; Hong S
J Med Chem; 2013 May; 56(9):3531-45. PubMed ID: 23600806
[TBL] [Abstract][Full Text] [Related]
6. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
Huang WS; Metcalf CA; Sundaramoorthi R; Wang Y; Zou D; Thomas RM; Zhu X; Cai L; Wen D; Liu S; Romero J; Qi J; Chen I; Banda G; Lentini SP; Das S; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Zhou T; Commodore L; Narasimhan NI; Mohemmad QK; Iuliucci J; Rivera VM; Dalgarno DC; Sawyer TK; Clackson T; Shakespeare WC
J Med Chem; 2010 Jun; 53(12):4701-19. PubMed ID: 20513156
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
Li Y; Shen M; Zhang Z; Luo J; Pan X; Lu X; Long H; Wen D; Zhang F; Leng F; Li Y; Tu Z; Ren X; Ding K
J Med Chem; 2012 Nov; 55(22):10033-46. PubMed ID: 23088644
[TBL] [Abstract][Full Text] [Related]
9. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
[TBL] [Abstract][Full Text] [Related]
10. Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo.
Yuan X; Zhang Y; Zhang H; Jin J; Li X; Liu H; Feng Z; Chen X
Leuk Res; 2011 Feb; 35(2):237-42. PubMed ID: 20739063
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of pyridin-3-yl pyrimidines as potent Bcr-Abl inhibitors.
Pan X; Dong J; Gao H; Wang F; Zhang Y; Wang S; Zhang J
Chem Biol Drug Des; 2014 May; 83(5):592-9. PubMed ID: 24330598
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR-ABL kinase inhibitors.
Hu L; Zheng Y; Li Z; Wang Y; Lv Y; Qin X; Zeng C
Bioorg Med Chem; 2015 Jul; 23(13):3147-52. PubMed ID: 26022079
[TBL] [Abstract][Full Text] [Related]
13. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
14. Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase.
Liu X; Kung A; Malinoski B; Prakash GK; Zhang C
J Med Chem; 2015 Dec; 58(23):9228-37. PubMed ID: 26562217
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
Asaki T; Sugiyama Y; Hamamoto T; Higashioka M; Umehara M; Naito H; Niwa T
Bioorg Med Chem Lett; 2006 Mar; 16(5):1421-5. PubMed ID: 16332440
[TBL] [Abstract][Full Text] [Related]
16. A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.
Choi HG; Ren P; Adrian F; Sun F; Lee HS; Wang X; Ding Q; Zhang G; Xie Y; Zhang J; Liu Y; Tuntland T; Warmuth M; Manley PW; Mestan J; Gray NS; Sim T
J Med Chem; 2010 Aug; 53(15):5439-48. PubMed ID: 20604564
[TBL] [Abstract][Full Text] [Related]
17. Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.
Tintori C; Fallacara AL; Radi M; Zamperini C; Dreassi E; Crespan E; Maga G; Schenone S; Musumeci F; Brullo C; Richters A; Gasparrini F; Angelucci A; Festuccia C; Delle Monache S; Rauh D; Botta M
J Med Chem; 2015 Jan; 58(1):347-61. PubMed ID: 25469771
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
19. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV
Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018
[TBL] [Abstract][Full Text] [Related]
20. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
